Researchers have created an H5N1 avian influenza, or bird flu, vaccine that can be administered as a nasal spray. The influenza virus vector-based nasal spray vaccine platform was first developed ...

They had given patients oral supplements of vitamin D to reduce nasal inflammation and reverse the loss of the sense of smell the inflammation often causes. "It helped zero of 28 people," she said.

The presentations include post hoc analyses of clinical data prospectively collected from studies of diazepam nasal spray as an immediate-use seizure medication for treatment of episodes of frequent ...

Scientists have pioneered an influenza virus vector-based nasal spray vaccine platform and developed a nasal spray H5N1 avian influenza vaccine. During the early COVID-19 pandemic, this platform ...

The State Key Laboratory for Emerging Infectious Diseases at the University of Hong Kong (HKU) and the InnoHK Centre for Virology, Vaccinology and Therapeutics (CVVT) have pioneered an influenza virus ...

noting that spray-dried formulations of mRNA-based vaccine candidates aim to enable needle-free nasal administration, potentially achieving mucosal immunity. “Together, I believe we are well ...

--(BUSINESS WIRE)--Aerin Medical, Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced the publication of positive three-year results from VATRAC, a randomized ...

Milestone® Pharmaceuticals (NASDAQ:MIST) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for CARDAMYST™ ...

The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.

Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a challenge for Milestone Pharmaceutical in its 22 years. Now the wait will ...

The letter did not raise any concerns regarding clinical safety or efficacy data. The Food and Drug Administration (FDA) has issued a Complete Response Letter to Milestone Pharmaceuticals ...